Is CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.0% / 30% | 90.4% / 30% | 0.0% / 30% | 2276.18% / 5% | ✗ NOT HALAL |
| DJIM | 0.0% / 33% | 90.4% / 33% | 0.0% / 33% | 2276.18% / 5% | ✗ NOT HALAL |
| MSCI | 0.0% / 33% | 89.1% / 33% | 0.0% / 33% | 2276.18% / 5% | ✗ NOT HALAL |
| S&P | 0.0% / 33% | 90.4% / 33% | 0.0% / 33% | 2276.18% / 5% | ✗ NOT HALAL |
| FTSE | 0.0% / 33% | 89.1% / 33% | 0.0% / 50% | 2276.18% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 63.4% | |
| Operating Margin | -64859.4% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -86.5% | |
| Return on Assets (ROA) | -53.0% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$5M |
| Free Cash Flow | -$6M |
| Debt-to-Equity | 0.2 |
| Current Ratio | 26.0 |
| Total Assets | $7M |
Price & Trading
| Last Close | $1.98 |
| 50-Day MA | $1.92 |
| 200-Day MA | $2.67 |
| Avg Volume | 75K |
| Beta | 2.2 |
|
52-Week Range
$1.50
| |
About CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ)
Creative Medical Technology Holdings, Inc., a commercial-stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction, and FemCelz for the treatment of loss of genital sensitivity and dryness. It develops AlloStem (CELZ-201-DDT), a allogenic human perinatal tissue derived cell program, ImmCelz (CELZ-100), a personalized supercharged immune therapy platform; CELZ-201 CREATE-1, which is phase 2, for the treatment of type 1 diabetes; AlloStemSpine (CELZ 201 ADAPT), which is phase 2, for the treatment of chronic lower back pain; Alova, a platform to treat infertility as a result of premature ovarian failure; StemSpine, a regenerative stem cell procedure to treat degenerative disc disease; OvaStem, a stem cell therapy for premature ovarian failure; CaverStem for erectile dysfunction treatment; and FemCelz for female sexual function treatment. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.'s debt ratio?
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.'s debt ratio is 0.0% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.0%.
What are CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.'s key financial metrics?
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. has a market capitalization of $7M, and revenue of $11,000. Return on equity stands at -86.5%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.